Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890448 · ClinicalTrials.gov registry record
Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate
A clinical trial of Toxicity, sponsored by Takeda.
- Completed
- Registry status
- 66
- Enrollment target
- 19
- Study locations
NCT00890448: Completed study of Toxicity, sponsored by Takeda.
NCT00890448 is a study of Toxicity that has completed, run by Takeda. The registered enrollment target is 66 participants. The trial reports 19 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00890448, a study of Toxicity, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to examine the genetic contribution to the mechanism of lapaquistat acetate- induced hepatic abnormalities.
Conditions Studied
Interventions
- OTHER Pharmacogenomic whole blood sampling
Study Locations (19)
Other
- - Córdoba
- - Québec
- - Sainte-Foy
- - Santiago
- - Havírov-Šumbark
- - Oulu
- - Nuremberg
- - Riga
- - Groningen
- - Gdansk
- - Moscow
- - Saratov
- - Žilina
- - Johannesburg
Florida
- - Jacksonville
- - Jupiter
Idaho
- - Idaho Falls
Virginia
- - Richmond
Scotland
- - Glasgow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-05 |
What the finished NCT00890448 record still lists
NCT00890448 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target.
The record links to 1 condition, with Toxicity appearing as the primary indexed condition, and to 1 intervention - of which Pharmacogenomic whole blood sampling is the first listed.
NCT00890448 lists 19 locations in 5 states (Other, Florida, Idaho).
Frequently Asked Questions
What is clinical trial NCT00890448 about?
NCT00890448 is a clinical study titled "Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate". The purpose of this study is to examine the genetic contribution to the mechanism of lapaquistat acetate- induced hepatic abnormalities.
What is the current status of trial NCT00890448?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2009-05. Estimated completion is 2010-05.
What conditions does trial NCT00890448 study?
This clinical trial studies the following conditions: Toxicity.
What interventions are being tested in trial NCT00890448?
The interventions under investigation include: Pharmacogenomic whole blood sampling (OTHER).
Who is sponsoring clinical trial NCT00890448?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00890448 being conducted?
This trial has 19 study locations across Florida, Idaho, Virginia, Scotland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Toxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia